Bellicum Appoints Reid Huber, Ph.D. to Board of Directors

HOUSTON--()--Bellicum Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering and developing novel cellular immunotherapies, today announced the appointment of Reid M. Huber, Ph.D. to its Board of Directors.

Dr. Huber has over 16 years of experience in pharmaceutical research and clinical development, in both senior leadership and scientific research positions. He currently serves as Executive Vice President and Chief Scientific Officer at Incyte Corporation where he leads drug discovery research primarily in the area of hematology/oncology.

“Dr. Huber has an impressive track record of leading drug discovery research, and a depth of knowledge and understanding of immuno-oncology that is central to several of Bellicum’s clinical programs,” commented Tom Farrell, CEO of Bellicum Pharmaceuticals. “We look forward to the unique perspective Reid can bring to Bellicum as we advance our novel cell therapy product candidates.”

Added Dr. Huber, “I am eager to work closely with fellow Bellicum directors and the management team in helping to achieve the full potential of the Company’s promising controlled-cell therapies.”

Dr. Huber began his career at DuPont Pharmaceuticals in 1998 and was a founding member of the team that started drug discovery at Incyte Corporation in 2002. He received his B.S. in biochemistry/molecular genetics from Murray State University and his Ph.D. in molecular genetics from Washington University, and later trained at the National Institutes of Health.

About Bellicum Pharmaceuticals

Bellicum is a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company is using its proprietary Chemical Induction of Dimerization, or CID, technology platform to engineer and control components of the immune system in real time. The Company is developing next-generation product candidates in some of the most important areas of cellular immunotherapy, including hematopoietic stem cell transplantation, or HSCT, CAR T cell therapy, and dendritic cell vaccines. For more information, please visit www.bellicum.com.

Contacts

Investors:
Pete Rahmer, 646-378-2973
prahmer@troutgroup.com
or
Media:
Brad Miles, 646-513-3125
bmiles@bmccommunications.com
or
Amy Bonanno, 646-513-3117
abonanno@bmccommunications.com

Contacts

Investors:
Pete Rahmer, 646-378-2973
prahmer@troutgroup.com
or
Media:
Brad Miles, 646-513-3125
bmiles@bmccommunications.com
or
Amy Bonanno, 646-513-3117
abonanno@bmccommunications.com